A June FDA advisory committee will be a huge moment for struggling bluebird bio. A positive decision by FDA coupled with the favorable ICER assessment could lead to a robust cash flow. Being considered cost-effective may offer Zynteglo a distinct advantage in its negotiations with payers.
Subscribe to:
Post Comments (Atom)
< + > Provider Enrollment is a Data Problem Hiding in the Denial Queue
The following is a guest article by Madison Gardner, President at AMS Solutions, Inc. A claim can pass every check a practice controls and ...
No comments:
Post a Comment